Drug responses of AscleStem<sup>®</sup> Cardiomyocytes derived from nomal human iPS cells differentiated by 3D embryoid body formation protocol

DOI

Bibliographic Information

Other Title
  • 健常ヒトiPS細胞由来心筋細胞 AscleStem<sup>®</sup> Cardiomyocytesの薬剤応答性の評価

Description

<p>Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have been expected to provide new tools for regenerative medicine, drug discovery and safety assessment. Currently, some manufacturers supply their hiPSC-CMs, each of which is differentiated and purified in its own way from each iPS cells, therefore these cardiomyocytes show different characteristics from each other against drugs. Thus, it is necessary that a hiPSC-CM is characterized before assessment.</p><p>We have been offering "AscleStem® Cardiomyocytes" which are derived from human iPS cells differentiated with chemical compounds instead of cytokines by 3D embryoid body formation protocol, and purified with no antibiotics. In this study, we introduce "AscleStem® Cardiomyocytes" with drug-responses.</p>

Journal

Details 詳細情報について

  • CRID
    1390567172568225920
  • NII Article ID
    130007898280
  • DOI
    10.14869/toxpt.47.1.0_p-156
  • Text Lang
    ja
  • Data Source
    • JaLC
    • CiNii Articles
  • Abstract License Flag
    Disallowed

Report a problem

Back to top